Anti Vegf Eylea 2mg denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti vegf eylea 2mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Eylea (aflibercept 2 mg) for Step Therapy

A step-therapy ("fail first") denial means UHC's coverage policy requires that a patient try one or more preferred anti-VEGF agents — typically a lower-cost formulary alternative — before Eylea 2 mg will be approved. This is one of the most common denial types for branded anti-VEGF agents, and it is also one of the most frequently overturned, because many patients have already tried the preferred agent, or have a documented clinical reason why the preferred agent is inappropriate for them specifically.

## Why This Denial Is Appealable

Step-therapy requirements must yield to individual clinical circumstances under most plan documents and under step-therapy protection laws enacted in a growing number of states. The appeal succeeds when the record shows any of the following: (1) the patient already tried the required step-therapy drug and documented inadequate response or adverse effects; (2) the required drug is medically contraindicated or clinically unsuitable for this patient; or (3) the delay required to complete the step would result in irreversible vision loss or other serious harm. Many UHC commercial plans also include a step-therapy override provision that the prescriber can invoke directly.

## Your Federal Appeal Rights

• Step-therapy override request: Many UHC plans have a formal override pathway — file this with the prescriber's clinical justification before or alongside the formal appeal.
• Internal appeal (ERISA §503 / ACA): File within the deadline on your denial letter. The appeal must directly address each step-therapy requirement in UHC's policy and explain why it has been met or should be waived.
• External review (ACA §2719): If the internal denial stands, escalate to an IRO within approximately four months. Step-therapy denials that hinge on medical necessity are eligible for external review, and IROs regularly overturn them when the clinical record is complete.
• State step-therapy law: If you are on an individual or small-group plan, check whether your state has enacted step-therapy protection legislation, which may impose additional override criteria that are more favorable than the plan document.
• Expedited review: Request the 72-hour track if the step-therapy delay would cause irreversible harm.

## Documentation to Gather

1. Step-drug trial history — for each drug required by the step-therapy protocol, document the dates of use, the number of injections, and the objective clinical response (or documented reason the drug was not appropriate to try). 2. Comparative imaging — OCT and visual acuity data from the period on the step-therapy drug versus baseline or current status. 3. Prescriber step-therapy override letter — a detailed letter addressing UHC's override criteria, explaining why each required step has been satisfied or why proceeding to Eylea 2 mg is medically necessary without completing the step. 4. UHC step-therapy policy — obtain the current published policy; identify the required steps and override criteria, and map the prescriber's letter to each. 5. FDA label — include current prescribing information to confirm the indication and reinforce that the treatment is not experimental.

## Criteria-Mapping Structure

Step-therapy appeals have a two-part map. Part one covers each required step: was it completed (with dates and outcomes) or is there a clinical reason it should be waived (with the specific documented rationale)? Part two covers the standard medical-necessity criteria that apply once the step-therapy question is resolved. Presenting both parts in a structured table demonstrates to the reviewer — and to any subsequent IRO — that you have met every threshold for authorization.